RDHL 8.79 Redhill Biopharma Ltd $RDHL Hit a 52 week low of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 10:50 PM

RDHL 8.79 Redhill Biopharma Ltd $RDHL Hit a 52 week low of 8.21 Closing the day 11/10/14 at 8.79 -0.50 -5.38% With a day low of 8.21 and a total volume of 29,705.

RDHL Recent Posts: http://investorshangout.com/Redhill-Biopharma...DHL-89488/

RDHL Redhill Biopharma Ltd Recent Headline News

Redhill Biopharma's (RDHL) CEO Dror Ben Asher on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:01PM CST

RDHL: 8.79 (-0.50)

FDA tags RedHill's RHB-105 a QIDP
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:02AM CST

RDHL: 8.79 (-0.50)

Redhill beats by $0.44
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:11AM CST

RDHL: 8.79 (-0.50)

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105
GlobeNewswire - Mon Nov 10, 6:28AM CST
-- Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications)
RDHL: 8.79 (-0.50)

RedHill Biopharma Reports Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 5:30AM CST
-- A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III studies in gastrointestinal indications: RHB-104 for Crohn's disease, RHB-105 for H. pylori infection and RHB-102 for acute gastroenteritis and gastritis
RDHL: 8.79 (-0.50)

RedHill Bio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 9:39AM CDT

RDHL: 8.79 (-0.50)

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014
GlobeNewswire - Tue Oct 28, 6:15AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it will report financial results for the third quarter of 2014 on Monday, November 10, 2014.
RDHL: 8.79 (-0.50)

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference
GlobeNewswire - Wed Oct 22, 8:44AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"

, a Canadian drug delivery company focused on oral drug delivery, that they have submitted a Marketing Authorization Application ("MAA"

to the German Federal Institute for Drugs and Medical Devices ("BfArM"

seeking European marketing approval of RHB-103, an oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT. The brand name RIZAPORT for RHB-103 was also conditionally approved by the U.S. Food and Drug Administration ("FDA"

as part of the New Drug Application ("NDA"

review process in the U.S., subject to a Complete Response Letter ("CRL"

received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 8.79 (-0.50), IGX.VN: 0.400 (+0.010)

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that they have submitted a Marketing Authorization Application ("MAA"

to the German Federal Institute for Drugs and Medical Devices ("BfArM"

seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT(R). The brand name RIZAPORT(R) was also conditionally approved by the U.S. Food and Drug Administration ("FDA"

as part of the New Drug Application ("NDA"

review process in the U.S., subject to a Complete Response Letter ("CRL"

received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 8.79 (-0.50), IGX.VN: 0.400 (+0.010)

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment
GlobeNewswire - Tue Sep 16, 6:13AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at the 7 Annual BioPharm America International Partnering Conference, on Tuesday, September 23, 2014, at 2:45 p.m. EDT, in the Suffolk room of the Boston Marriott Copley Placein Boston, Massachusetts.
RDHL: 8.79 (-0.50)

Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - Thu Sep 11, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint
AGN: 195.24 (-0.76), RDHL: 8.79 (-0.50), MRK: 58.81 (-0.53), RVNC: 20.30 (+0.51), GSK: 45.16 (+0.25)

RedHill Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 11:30AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference, on Wednesday, September 10, 2014, at 1:40 p.m. EDT, in the Holmes II Salon of the New York Palace Hotel in New York City.
RDHL: 8.79 (-0.50)

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis
GlobeNewswire - Wed Sep 03, 6:00AM CDT
-- The randomized, double-blind, placebo-controlled, parallel group Phase III study with RHB-102 (the GUARD study) will enroll 320 acute gastroenteritis patients in the U.S.
RDHL: 8.79 (-0.50)

RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:40PM CDT
RedHill Biopharma Ltd. (RDHL) recently provided an update on the ongoing phase III study ERADICATE Hp, on pipeline candidate RHB-105 for Helicobacter pylori infection (H. pylori).
AGN: 195.24 (-0.76), RDHL: 8.79 (-0.50), GILD: 107.02 (+0.57), RGDO: 0.88 (-0.05)

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
GlobeNewswire - Wed Aug 27, 7:25AM CDT
-- In order to enhance statistical powering and expedite recruitment, RedHill has increased the number of subjects and clinical sites, respectively, in the ongoing RHB-105 Phase III ERADICATE Hp study, with top-line data currently expected in the first half of 2015
RDHL: 8.79 (-0.50)

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101
GlobeNewswire - Wed Aug 13, 9:15AM CDT
-- Potentially expanding its gastrointestinal-focused pipeline, RedHill has secured an option to acquire RP101 from Dresden-based RESprotect GmbH, a spin-off from the Fraunhofer-Society
RDHL: 8.79 (-0.50)

Redhill Biopharma Ltd. (RDHL) Stock Research Links

RDHL Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCOM Secures $600M Deal to Boost NATO's Defense

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

Epson & The Photo Managers Highlight Memories in Sept.

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Zum Drivers Shine as New School Year Begins

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Supercharged Entertainment's Big Bet in Ohio's Polaris

Fasten your seatbelts, folks—because there's a tinge of burnt rubber in the air at Columbus's Polaris Center. Supercharged Entertainment, the big guns in indoor karting, just kicked off construction at their brand-new venue, and it’s looking like a gearhead's paradise. A sprawling 16-acre parcel is set to become a haven for adrenaline junkies come Summer 2027. A Bold...

Immunic Pushes Boundaries in MS with Vidofludimus

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Axjo Group Expands in France with Eco-Tourets Buy

Seizing the French Market: Axjo's Strategic Play Every now and then, you come across a company that's not just talking the talk but walking the green walk. Axjo Group's latest move—scooping up France's Eco-Tourets—puts them squarely in that league. It ain't just about expanding the footprint; it's about owning a piece of the future where sustainability isn't a...

Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Early Education's Massive Impact: Key Skills for Success

Unlocking Lifelong Success: The Early Advantage Ever look at a successful adult and wonder, "Where'd they get that spark?" According to HelloNation and child care expert Karen Ego, it all starts early. Think of early learning not just as prepping for school, but as the first blueprint for life's journey. It's the skills you pick up in those tender years that stick it out...

Innventure Faces Class Action Over Alleged Deception

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...